Company Overview
Gelteq Limited operates within the healthcare sector, specifically functioning as a drug manufacturer in the specialty and generic space, with a primary focus on developing and commercializing white label gel-based delivery solutions for humans and animals across the United States and Australia. The company's product portfolio includes edible gels designed for prescription drugs, nutraceuticals, pet care products, sports applications, and over-the-counter items, addressing a niche market for specialized delivery mechanisms. As a micro-cap entity, Gelteq Limited currently holds a market capitalization of $7.82M and employs a small workforce of 7 individuals, indicating a lean operational structure typical of early-stage development firms. The combination of a market cap under $10 million and annual revenue of $413,132 suggests that the company is in a growth phase where revenue generation is prioritized over profitability, reflecting the capital-intensive nature of drug manufacturing and commercialization efforts.
Financial Health
The company reported a trailing twelve-month revenue of $413,132 against a net income of $-6,645,453 and an EBITDA of $-3,843,531, revealing a significant disparity between top-line sales and bottom-line earnings that points to substantial operating expenses or one-time charges impacting profitability. Free cash flow stands at $-5,006,946, indicating that current operations are consuming cash reserves rather than generating liquidity, which limits immediate financial flexibility for capital expenditures without external financing. Gross margin is recorded at 72.1%, suggesting efficient production costs relative to sales, whereas the operating margin of -2969.4% and profit margin of 0.0% highlight severe operational losses that are not yet reflected in the final bottom line. On the balance sheet, the company holds $344,648 in cash while carrying $4.22M in debt, resulting in a debt-to-equity ratio of 26.68, which characterizes a highly leveraged financial position where liabilities significantly outweigh equity. The current ratio of 0.27 indicates that current assets are insufficient to cover current liabilities, signaling potential short-term liquidity challenges that could impact the company's ability to meet obligations without refinancing or additional funding. Return on equity is -43.0% and return on assets is -15.0%, metrics that demonstrate management is currently destroying shareholder value and utilizing assets inefficiently in the context of generating positive returns.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is N/A, a status that implies earnings are currently negative and prevents the use of standard price-to-earnings multiples to gauge valuation based on historical or projected profitability. The price-to-book ratio is 0.67, indicating that the market values the company at roughly two-thirds of its book value, which often occurs when investors price in significant distress or expect a restructuring of the capital base. Price-to-sales stands at 18.93 and EV/EBITDA is -3.04, suggesting that while the revenue multiple is elevated for a loss-making company, the negative EV/EBITDA reflects the heavy debt load and lack of earnings power relative to enterprise value. The stock has traded between a 52-week high of $4.11 and a 52-week low of $0.64, meaning the current valuation sits within a wide historical range that reflects high volatility typical of small-cap healthcare stocks. The beta value is N/A, which indicates that there is insufficient historical price data relative to the broader market to calculate volatility, leaving the risk profile relative to market movements undefined for this specific security.
Growth & Income
Revenue growth year-over-year is 59.4%, demonstrating a rapid expansion in sales volume, whereas earnings growth is N/A due to the absence of positive net income, implying that top-line expansion is not yet translating into bottom-line profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available cash is being retained to fund operations, R&D, or debt reduction rather than being distributed to shareholders. The absence of a dividend payout indicates a strategy focused on reinvesting earnings into growth initiatives to eventually achieve profitability, rather than providing current income to investors. The overall growth and income profile presents a high-risk, high-revenue-growth scenario where the company is sacrificing immediate shareholder returns to pursue market expansion and operational scaling in the specialized gel delivery market.